Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer

• Published in: FEBS letters Vol. 579; no. 13; pp. 2873 - 2877
• Main Authors: Chang, Jong Wook, Lee, Seung Hee, Jeong, Ju Yeon, Chae, Ho Zoon, Kim, Young Chul, Park, Zee-Yong, Yoo, Yung Joon
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 23.05.2005
• Subjects: 2-DE; Adult; Aged; Aged, 80 and over; Autoantibody; Carcinoma, Non-Small-Cell Lung - immunology; Electrophoresis, Polyacrylamide Gel; Female; Heat-Shock Proteins - immunology; Heat-Shock Proteins - physiology; Humans; Immunohistochemistry; Lung Neoplasms - immunology; Male; Middle Aged; Non-small cell lung cancer; NSCLC; Peroxidases - immunology; Peroxidases - physiology; peroxiredoxin; Peroxiredoxin-I; Peroxiredoxins; Prx; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor antigen; two-dimensional electrophoresis; Peroxiredoxin-I; NSCLC; Tumor antigen; Prx; Non-small cell lung cancer; Autoantibody; 2-DE
• ISSN: 0014-5793; 1873-3468
• DOI: 10.1016/j.febslet.2005.04.028

In eukaryotic cells, peroxiredoxins are both antioxidants and regulators of H 2O 2-mediated signaling. We previously found that peroxiredoxin-I (Prx-I) was overexpressed in non-small cell lung cancer (NSCLC) tissue. Since overexpressed protein can induce a humoral immune response, we examined whether serum from NSCLC patients exhibited immunoreactivity against Prx-I using Western blotting. We found that 25 (47%) of 53 NSCLC patients tested had autoantibodies against Prx-I in their sera, whereas such activity was detected in 4 (8%) sera from 50 healthy subjects. Prx-I itself was detected in the sera from 18 (34%) of 53 NSCLC patients but in only 1 (2%) serum from 50 controls. Moreover, 17% of NSCLC sera were positive to both Prx-I antibody and antigen but none in control sera. The data indicate both Prx-I autoantibody and circulating antigen are potential biomarkers for use in serological diagnosis of NSCLC. Interestingly enough, we found that Prx-I was secreted by lung adenocarcinoma cells (A549) but not by non-cancer lung cells (BEAS 2B) or breast cancer cells (MCF7). This cell culture study suggests the possibility of Prx-I secretion from NSCLC tumor tissues.